Feng Yang’s lab at Baylor College of Medicine published a study in the Proceedings of the National Academy of Sciences, which looked into what drives the growth of advanced tumors that have become resistant to standard castration therapy. Working with cells in the lab and animal models, they discovered an approach that suppresses the growth of therapy-resistant tumors.
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have validated a test that can accurately predict which patients with prostate cancer are at higher risk of developing long-lasting urinary side effects after receiving radiation therapy.
